Everyone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the market in late 2022. You might think it’s way too late to invest in AI. But here’s the thing.

Christopher P. Lowe net worth and biography

Christopher Lowe Biography and Net Worth

CFO of Cortexyme

Christopher Lowe has served as our Chief Operating Officer since February 2021, Chief Financial Officer since January 2019 and as our Treasurer since April 2019. From June 2018 until January 2019, Mr. Lowe served as a consultant to us and our interim Chief Financial Officer through his capacity as a partner at FLG Partners. Mr. Lowe has also served as the Managing Partner of the Innventus Fund at Innventure since January 2017 and he has served as a partner at FLG Partners since January 2014 and its Managing Partner since January 2018. Prior to joining Cortexyme, Mr. Lowe served as the Interim Chief Executive Officer and Chief Financial Officer of Hansen Medical from February 2014 to July 2016, and he served as the Chief Business Officer and Chief Financial Officer of Anthera Pharmaceuticals from September 2007 to June 2013. Mr. Lowe served as a director for Inspyr Therapeutics from September 2016 to December 2018. He also served as a director of EpiBiome from May 2016 to June 2018, and he served as a director and Chairman of the Audit Committee for Asante Solutions from December 2014 to October 2015. Mr. Lowe holds a B.S. in Business Administration from California Polytechnic State University and an M.B.A. from St. Mary’s University.

What is Christopher P. Lowe's net worth?: The estimated net worth of Christopher P. Lowe is at least $50,552.00 as of August 24th, 2022. Mr. Lowe owns 28,400 shares of Cortexyme stock worth more than $50,552 as of December 22nd. This net worth estimate does not reflect any other assets that Mr. Lowe may own. Learn More about Christopher P. Lowe's net worth.
How do I contact Christopher P. Lowe?: The corporate mailing address for Mr. Lowe and other Cortexyme executives is 269 EAST GRAND AVE, SOUTH SAN FRANCISCO CA, 94080. Cortexyme can also be reached via phone at (650) 910-5717 and via email at [email protected]. Learn More on Christopher P. Lowe's contact information.
Has Christopher P. Lowe been buying or selling shares of Cortexyme?: Christopher P. Lowe has not been actively trading shares of Cortexyme over the course of the past ninety days. Most recently, Christopher P. Lowe sold 4,963 shares of the business's stock in a transaction on Tuesday, October 5th. The shares were sold at an average price of $98.50, for a transaction totalling $488,855.50. Learn More on Christopher P. Lowe's trading history.
Who are Cortexyme's active insiders?: Cortexyme's insider roster includes Michael Detke (Insider), Stephen Dominy (Insider), David Lamond (Director), Christopher Lowe (CFO), Casey Lynch (CEO), and Margaret Mcloughlin (Director). Learn More on Cortexyme's active insiders.

Christopher P. Lowe Insider Trading History at Cortexyme

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
10/5/2021	Sell	4,963	$98.50	$488,855.50
8/16/2021	Sell	22,000	$95.31	$2,096,820.00

Christopher P. Lowe Buying and Selling Activity at Cortexyme

Cortexyme Company Overview

Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection. The company was incorporated in 2012 and is headquartered in South San Francisco, California.

Today's Range

Now: $1.78

$1.74

$1.85

50 Day Range

MA: $1.61

$0.69

$2.16

2 Week Range

Now: $1.78

$1.78

$40.66

Volume

106,261 shs

Average Volume

620,672 shs

Market Capitalization

$53.67 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.4

$2 Trillion Disappears Because of Fed's Secretive New Move

From Stansberry Research | Ad

$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being carried out by the Fed that has nothing to do with lowering or raising interest rates... but could soon have an enormous impact on your wealth.

Click here to see his new research now.